Little House Capital LLC Has $1.17 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Little House Capital LLC lowered its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 38.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,473 shares of the medical research company's stock after selling 2,840 shares during the period. Little House Capital LLC's holdings in Amgen were worth $1,166,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. AMF Tjanstepension AB increased its holdings in shares of Amgen by 16.9% during the 3rd quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company's stock valued at $38,825,000 after acquiring an additional 17,387 shares during the last quarter. Creative Planning lifted its holdings in Amgen by 8.6% in the 3rd quarter. Creative Planning now owns 197,457 shares of the medical research company's stock worth $63,402,000 after purchasing an additional 15,564 shares during the last quarter. Swedbank AB boosted its position in Amgen by 1.1% during the third quarter. Swedbank AB now owns 538,899 shares of the medical research company's stock worth $173,639,000 after purchasing an additional 5,751 shares during the period. Cornerstone Wealth Management LLC grew its holdings in Amgen by 73.2% during the third quarter. Cornerstone Wealth Management LLC now owns 2,270 shares of the medical research company's stock valued at $732,000 after purchasing an additional 959 shares during the last quarter. Finally, nVerses Capital LLC raised its position in shares of Amgen by 800.0% in the third quarter. nVerses Capital LLC now owns 900 shares of the medical research company's stock valued at $290,000 after purchasing an additional 800 shares during the period. Institutional investors own 76.50% of the company's stock.

Amgen Price Performance

Amgen stock traded up $1.47 on Wednesday, reaching $294.27. The company's stock had a trading volume of 2,806,841 shares, compared to its average volume of 3,145,679. The business's fifty day moving average price is $274.73 and its 200 day moving average price is $300.81. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The company has a market cap of $158.18 billion, a price-to-earnings ratio of 38.98, a PEG ratio of 2.53 and a beta of 0.56. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Equities analysts expect that Amgen Inc. will post 20.6 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a $2.38 dividend. This is a positive change from Amgen's previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.24%. The ex-dividend date of this dividend is Friday, February 14th. Amgen's dividend payout ratio is currently 126.09%.

Analysts Set New Price Targets

AMGN has been the subject of several recent analyst reports. Wells Fargo & Company decreased their price objective on shares of Amgen from $335.00 to $280.00 and set an "equal weight" rating for the company in a report on Friday, January 10th. Piper Sandler raised their price target on Amgen from $310.00 to $329.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. Leerink Partners dropped their price objective on Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. William Blair restated an "outperform" rating on shares of Amgen in a research note on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft cut their price target on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Amgen currently has an average rating of "Hold" and a consensus price target of $314.09.

Insider Buying and Selling at Amgen

In other Amgen news, EVP Jonathan P. Graham sold 25,045 shares of the firm's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the transaction, the executive vice president now owns 28,987 shares in the company, valued at approximately $8,496,669.44. This trade represents a 46.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Murdo Gordon sold 8,771 shares of the company's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total value of $2,585,603.09. Following the completion of the sale, the executive vice president now directly owns 44,186 shares of the company's stock, valued at approximately $13,025,590.94. This trade represents a 16.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 35,405 shares of company stock valued at $10,410,596. 0.69% of the stock is currently owned by insiders.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.